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A brief introduction to the short QT syndrome
Congenital short QT syndrome (SQTS) is a rare condition 
characterized by abbreviated rate-corrected QT (QTc) intervals 
on the electrocardiogram, often accompanied by tall T waves, 
and by poor rate adaptation of the QT interval [1-3]. It is 
associated with an increased incidence of atrial and ventricular 
arrhythmias and with an increased risk of sudden death [1-3]. 
European Society of Cardiology guidelines suggest a diagnosis of 
SQTS with a QTc interval of ≤ 340 ms [4]. QTc intervals exceeding 
this value but of ≤ 360 ms may be indicative of SQTS if there is 
evidence of one or more of: a familial history of SQTS or sudden 
death below age 40, survival from ventricular tachycardia (VT) 
or fibrillation (VF) in the absence of structural heart disease 4, 
or presence of a confirmed pathogenic mutation [4]. Thus far, 
eight distinct genetic SQTS variants have been identified that are 
associated with mutations to ion channels or transporters [3]. 
However, a relatively low proportion of patients who undergo 
genotyping (approximately 1 in 4 tested [5]) yield a mutation 
in an identified SQTS candidate gene, indicating that there is 
still much to discover about the underlying basis of QTc interval 
abbreviation in this condition. This brief article highlights why 
primary carnitine deficiency (PCD) should be evaluated as a 
potential cause of SQTS where examination of other genetic 
candidates proves negative.
An introduction to primary carnitine deficiency
Carnitine is a naturally occurring amino-acid obtained 
in the diet from meat and dairy produce and also produced 
endogenously in the liver and kidneys. L-carnitine is highly 
polar and is a critical metabolic cofactor, driving carnitine 
palmitoyltransferase I (CPTI), which is a rate-limiting step in the 
uptake into mitochondria and oxidation of long chain fatty acids 
(LCFAs) [6-10]. LCFAs are important energy sources in muscular 
tissue but cannot freely diffuse across the inner mitochondrial 
membrane [10]. Deficiency of carnitine therefore inhibits 
mitochondrial oxidation of LCFAs, leading to lipid accumulation 
in the cell cytosol. Active uptake of L-carnitine into the heart is 
controlled by the organic cation transporter 2 (OCTN2) encoded 
by the SLC22A5 gene [11,12].
Primary carnitine deficiency (PCD; OMIM 212140) is a rare but 
potentially fatal genetic disorder characterised by low plasma 
carnitine levels and a deficiency of intracellular carnitine. It exists 
as an autosomal recessive disorder, due to mutations in the 
SLC22A5 gene that encodes the high affinity, sodium-dependent 
carnitine transporter, OCTN2 (OMIM 603377), and is associated 
with metabolic crisis, hepatic encephalopathy and sudden 
death [10,13-15]. Carnitine levels in PCD are low intracellularly 
and plasma and high in urine (due to renal wasting). A cardiac 
manifestation of PCD is common (with one review reporting a 
> 60% exclusive cardiac manifestation [15]): patients develop 
a progressive cardiomyopathy, which is responsive to carnitine 
supplementation. Without diagnosis and treatment PCD patients 
develop lethal heart failure [10,15]. More than 100 disease 
causing mutations in SLC22A5 have been identified [15], with 
variable correlation between genotype and phenotype, possibly 
due to a role for external influences in exacerbating or mitigating 
clinical phenotype [15,16].
Primary carnitine deficiency, arrhythmias and 
abbreviated repolarization
Cardiac arrhythmias have been described in both PCD 
patients and heterozygous carriers of SLC22A5 mutations [10]. 
There is long-standing evidence that PCD leads to repolarization 
abnormalities. In 1981, T wave modification (tall, peaked T 
Abstract
Congenital forms of short QT syndrome (SQTS) are associated with QT interval abbreviation on the electrocardiogram, with atrial and ventricular 
arrhythmias and with an increased risk of sudden death. Whilst mutations in a number of ion channel and transporter genes have been identified 
in SQTS patients, often the underlying basis of the condition is not identified. This article briefly surveys evidence that primary carnitine deficiency 
(PCD), which arises from mutations in the SLC22A5 gene, may be a cause of SQTS. Experimental evidence linking carnitine deficiency with accelerated 
repolarization is also discussed and a case made for the imperative for further work to understand underlying mechanisms of low-carnitine induced 
repolarization abbreviation.
*Corresponding author: Jules C Hancox, School of Physiology, 
Pharmacology and Neuroscience, Medical Sciences Building, University 
Walk, Bristol, BS8 1TD United Kingdom, E-mail: jules.hancox@bristol.ac.uk
Received: July 18, 2018; Accepted: July 24, 2018; Published: July 27, 
2018
Citation: Hancox JC (2018) Primary carnitine deficiency as a potential cause of short QT syndrome
11Card Res Med, 2018; Volume 2, Issue 1
regulate activities of different ion channels [21] and highlighted 
a possible role of the hERG/rapid delayed rectifier (IKr) current in 
mediating effects of carnitine deficiency as previous work had 
shown regulation of function of “hERG” (the channel underling 
IKr) by long-chain acyl-carnitines [24].
The need for further experimental investigation
The available information, summarised in the foregoing text, 
appears to be sufficient to indicate a causal relationship between 
PCD and QTc interval shortening. It is worth noting, however, that 
PCT may also present atypically with QTc prolongation [25] and 
this highlights a need to understand more deeply the relationship 
between OCTN2 dysfunction and cardiac repolarization 
mechanisms. Roussel and colleagues recommended that Class III 
antiarrhythmic drugs be employed to test the role of potassium 
currents in their mouse model of carnitine-deficiency linked QT 
interval shortening [21]. The changes to repolarization seen in 
the mouse PCD model certainly warrant further exploration at 
the cellular electrophysiology level, in order to understand the 
underlying basis of altered repolarization. It seems unlikely, 
however, that changes to IKr would be an explanation for their 
observations [21]. This is because the comparatively abbreviated 
mouse ventricular action potential differs markedly from that in 
humans and other animals that possess action potentials with 
a high plateau phase, and mouse ventricular myocytes rely on 
other currents than IKr to drive repolarization [26]. Thus, the 
primary effects on repolarization in the murine MET-88 induced 
carnitine deficiency model are far more likely to be attributable to 
effects on other ionic conductances and this merits experimental 
exploration. Furthermore, given the importance of IKr to human 
ventricular repolarization [27,28] and the ability of LCFA to 
modulate hERG channel function [24], it seems imperative 
also to develop an experimental model of PCD, perhaps using 
MET-88 [21], that uses a species with ventricular repolarization 
mechanisms closer to those in humans. Such work is likely to 
provide novel insights into pathophysiological modulation of 
ventricular repolarization and may highlight novel intervention 
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